Professor Stephen Mackinnon leads the bone marrow and stem cell program at University College London. He attended medical school at the University of Glasgow. He subsequently trained in internal medicine and haemato-oncology in Glasgow. This was followed by a transplant fellowship at the Hammersmith Hospital in London where he developed an interest in graft-versus-leukaemia reactions.
In 1990 he moved to Memorial Sloan Kettering Cancer Center in New York to continue this work in both the clinic and the lab. He made the use of donor lymphocytes less toxic by limiting the T cell dose administered to transplant recipients allowing separation of graft-versus-leukaemia responses from graft-versus-host disease.
In 1995 he returned to London to his current position. In recent years he has developed an interest novel conditioning regimens. Current research interests include adoptive immunotherapy and immune reconstitution following allogeneic stem cell transplantation. The program has world class transplant outcomes for patients with leukaemia and lymphoma.
- Bone marrow transplantation
- Novel conditioning regimens
- Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A, Clark F, Yung L, Linch DC, Chakraverty R, Peggs KS, Mackinnon S. Favorable long-term survival following reduced intensity allogeneic transplantation for multiply relapsed aggressive non-Hodgkins Lymphoma J Cin Oncol 2009, 27:426-32
- Lambert JR, Bomanji JB, Peggs KS, Thomson KJ, Chakraverty RK, Fielding AK, Kottaridis PD, Roughton M, Morris EC, Goldstone AH, Linch DC, Ell PJ, Mackinnon S. Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood. 2010 115:2763-8
- Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G, Bloor AJ, Clark F, Kazmi M, Linch DC, Chakraverty R, Peggs KS, Mackinnon S. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol. 2010 28:3695-700
- Peggs KS, Kayani I, Chowdhry N, Kottaridis P, Goldstone AH, Linch DC, Hough R, Morris EC, Fielding A, Chakraverty R, Thomson KJ, Mackinnon S. Donor-lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients following T cell-depleted allogeneic transplantation for Hodgkin Lymphoma. J Clin Oncol. 2011 (in press)